Short Interest in AC Immune SA (NASDAQ:ACIU) Increases By 23.5%

AC Immune SA (NASDAQ:ACIU - Get Free Report) saw a large increase in short interest in October. As of October 31st, there was short interest totalling 984,500 shares, an increase of 23.5% from the October 15th total of 796,900 shares. Currently, 1.6% of the company's stock are sold short. Based on an average trading volume of 92,100 shares, the short-interest ratio is currently 10.7 days.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ACIU. Assenagon Asset Management S.A. grew its holdings in shares of AC Immune by 294.7% during the second quarter. Assenagon Asset Management S.A. now owns 439,730 shares of the company's stock valued at $1,755,000 after buying an additional 328,312 shares during the last quarter. Renaissance Technologies LLC grew its position in AC Immune by 26.4% during the second quarter. Renaissance Technologies LLC now owns 652,079 shares of the company's stock valued at $2,602,000 after buying an additional 136,300 shares during the period. Cubist Systematic Strategies LLC acquired a new position in AC Immune in the 2nd quarter worth about $218,000. Vanguard Capital Wealth Advisors acquired a new stake in AC Immune in the 2nd quarter valued at $56,000. Finally, Lazard Asset Management LLC acquired a new position in shares of AC Immune during the 1st quarter worth about $30,000. 51.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on ACIU shares. StockNews.com lowered shares of AC Immune from a "buy" rating to a "hold" rating in a report on Tuesday, October 1st. HC Wainwright restated a "buy" rating and set a $16.00 target price on shares of AC Immune in a report on Friday.

AC Immune Trading Down 7.9 %

Shares of NASDAQ:ACIU traded down $0.28 during trading on Friday, reaching $3.27. The stock had a trading volume of 163,250 shares, compared to its average volume of 344,507. The firm's 50-day simple moving average is $3.27 and its 200 day simple moving average is $3.47. AC Immune has a one year low of $2.25 and a one year high of $5.14. The company has a market capitalization of $323.53 million, a P/E ratio of -7.17 and a beta of 1.28.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.